189 related articles for article (PubMed ID: 15853662)
1. Receptor tyrosine kinases and anticancer therapy.
Medinger M; Drevs J
Curr Pharm Des; 2005; 11(9):1139-49. PubMed ID: 15853662
[TBL] [Abstract][Full Text] [Related]
2. Receptor tyrosine kinases: the main targets for new anticancer therapy.
Drevs J; Medinger M; Schmidt-Gersbach C; Weber R; Unger C
Curr Drug Targets; 2003 Feb; 4(2):113-21. PubMed ID: 12558064
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinases as targets in cancer therapy - successes and failures.
Traxler P
Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
[TBL] [Abstract][Full Text] [Related]
4. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
5. Protein tyrosine phosphatases as novel targets in breast cancer therapy.
Nunes-Xavier CE; Martín-Pérez J; Elson A; Pulido R
Biochim Biophys Acta; 2013 Dec; 1836(2):211-26. PubMed ID: 23756181
[TBL] [Abstract][Full Text] [Related]
6. [Antineoplastic agents targeting tyrosine kinases].
Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
[TBL] [Abstract][Full Text] [Related]
7. Cell signalling: growth factors and tyrosine kinase receptors.
Perona R
Clin Transl Oncol; 2006 Feb; 8(2):77-82. PubMed ID: 16632420
[TBL] [Abstract][Full Text] [Related]
8. The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone derivatives is mediated through the inhibition of receptor tyrosine kinases.
Lee JS; Kang Y; Kim JT; Thapa D; Lee ES; Kim JA
Eur J Pharmacol; 2012 Feb; 677(1-3):22-30. PubMed ID: 22200628
[TBL] [Abstract][Full Text] [Related]
9. SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias.
Bourrié B; Brassard DL; Cosnier-Pucheu S; Zilberstein A; Yu K; Levit M; Morrison JG; Perreaut P; Jegham S; Hilairet S; Bouaboula M; Penarier G; Guiot C; Larroze-Chicot P; Laurent G; Demur C; Casellas P
Leuk Lymphoma; 2013 Jul; 54(7):1488-99. PubMed ID: 23121564
[TBL] [Abstract][Full Text] [Related]
10. Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis.
Kim M; Baek M; Kim DJ
Curr Pharm Des; 2017 Nov; 23(29):4226-4246. PubMed ID: 28625132
[TBL] [Abstract][Full Text] [Related]
11. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
Wang X; Chen Z; Tong L; Tan S; Zhou W; Peng T; Han K; Ding J; Xie H; Xu Y
Eur J Med Chem; 2013 Jul; 65():477-86. PubMed ID: 23770449
[TBL] [Abstract][Full Text] [Related]
12. Receptor tyrosine kinase inhibitors: Are they real tumor killers?
Gaumann AK; Kiefer F; Alfer J; Lang SA; Geissler EK; Breier G
Int J Cancer; 2016 Feb; 138(3):540-54. PubMed ID: 25716346
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
14. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
15. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
Grimm CF; Blum HE; Geissler M
Dtsch Med Wochenschr; 2005 May; 130(21):1318-22. PubMed ID: 15902620
[No Abstract] [Full Text] [Related]
16. Directed therapies in lung cancer: new hope?
Parente Lamelas I; Abal Arca J; Fírvida Pérez JL
Arch Bronconeumol; 2012 Oct; 48(10):367-71. PubMed ID: 22551924
[TBL] [Abstract][Full Text] [Related]
17. Receptor tyrosine kinases and targeted cancer therapeutics.
Takeuchi K; Ito F
Biol Pharm Bull; 2011; 34(12):1774-80. PubMed ID: 22130229
[TBL] [Abstract][Full Text] [Related]
18. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
19. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
Bäckman U; Christofferson R
Pediatr Res; 2005 May; 57(5 Pt 1):690-5. PubMed ID: 15718357
[TBL] [Abstract][Full Text] [Related]
20. Targeting receptor tyrosine kinases in solid tumors.
Zhang J; Hochwald SN
Surg Oncol Clin N Am; 2013 Oct; 22(4):685-703. PubMed ID: 24012395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]